| 摘要 |
<P>PROBLEM TO BE SOLVED: To provide a phamaceutical aerosol preparation for dihydroergotamine or its phamaceutically allowable salt for administering dry powder suspended in an injection agent by pulmonary aerosol or intranasal spray. <P>SOLUTION: The preparation can be used for treatment of various conditions and diseases including migraine. It is manufactured by a supercritical fluid technique and contains a granular agent mixed with powder and a hydrofluoroalkane injection agent that is a mixture of (ii) 1,1,1,2-tetrafluroethane and 1.1.1.2.3.3.3-heptafluoro-n-propane. This preparation is a stable pharmaceutical aerosol preparation that contains the granular agent mixed with powder being ≥10 μ in average particle size and does not contain a surfactant. This preparation is superior in stability and purity and contains particles having an inhalable particle size best suited to pulmonary delivery. <P>COPYRIGHT: (C)2012,JPO&INPIT |
